Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

108.60 -3.00 (-2.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
72 73 Next >
News headline image
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
News headline image
BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion ↗
For the year, BioNTech said it expects about $5.4 billion in sales of its Covid shot. 
Via Investor's Business Daily
News headline image
Why BioNTech Shares Are Trading Lower Today ↗
BioNTech SE (NASDAQ: BNTX) shares are falling in the premarket session today after the company reported Q4 earnings and expected lower annual revenue from the Covid-19 vaccine. 
Via Benzinga
News headline image
BioNTech Earnings Preview ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About BioNTech ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: BioNTech ↗
 
Via Benzinga
News headline image
BioNTech Q4 2022 Earnings Conference Call On March 27, 2023 At 08:00 AM ET ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 27, 2023 ↗
Companies Reporting Before The Bell • Viomi Technology Co (NASDAQ:VIOT) is likely to report earnings for its fourth quarter. • Vislink Technologies (NASDAQ:VISL) is projected to report earnings for its... 
Via Benzinga
News headline image
US Stocks Poised To Start New Trading Week Higher On Hopes Of Resolving Banking Crisis: Analyst Warns 'No News Would Be Good News' ↗
The recent positive momentum seen in the market could carry over into the new week, as indicated by the index futures, which were holding up early Monday. 
Via Benzinga
News headline image
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
Could CRISPR Therapeutics Become the Next Moderna? ↗
Both companies use cutting-edge technology. 
Via The Motley Fool
News headline image
Carnival, BioNTech And 3 Stocks To Watch Heading Into Monday ↗
With US futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Investor Fear Increases Amid Recent Bank Concerns ↗
The CNN Money Fear and Greed index showed some increase in the fear level among U.S. investors. US stocks closed higher on Friday following a volatile trading session. All the major indices recorded... 
Via Benzinga
News headline image
7 Blue-Chip Stocks Sitting in the Sweet Spot ↗
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
News headline image
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine ↗
Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization. 
Via Benzinga
News headline image
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks ↗
The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk. 
Via Benzinga
News headline image
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders ↗
Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans. 
Via Investor's Business Daily
News headline image
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information ↗
 
Via Benzinga
News headline image
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose ↗
From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. 
Via Benzinga
News headline image
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
From BioNTech SE
Via GlobeNewswire
News headline image
7 Stocks Set to Soar When the Market Recovers ↗
Daring contrarians can bid up the danger with these intriguing market ideas. 
Via InvestorPlace
News headline image
FDA Approves Pfizer/BioNTech's Bivalent COVID-19 Vaccine For Youngest Kids ↗
 
Via Benzinga
News headline image
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines? ↗
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr. 
Via Benzinga
News headline image
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
From BioNTech SE
Via GlobeNewswire
News headline image
Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential ↗
They're both facing the same fierce headwind, and it won't be going away soon. 
Via The Motley Fool
News headline image
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising ↗
 
Via Benzinga
News headline image
European Commission Keeps Mum On Talks Regarding Pfizer COVID-19 Vaccine Contract: Report ↗
European Commission President Ursula von der Leyen remains silent on her dealings with Pfizer Inc (NYSE: PFE) regarding the EU's COVID-19 vaccine contract is hurting public trust. 
Via Benzinga
News headline image
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
From BioNTech SE
Via GlobeNewswire
News headline image
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks ↗
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.